PALVELLA THERAPEUTICS INC. - COMMON STOCK

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

05 May 2025 07:30:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

23 Apr 2025 16:15:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

22 Apr 2025 07:29:59 By Nasdaq GlobeNewswire

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

11 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

04 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

02 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

18 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

25 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

10 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

08 Jan 2025 08:00:01 By Nasdaq GlobeNewswire